BriaCell Therapeutics Corp. (BCTX)

NASDAQ: BCTX · IEX Real-Time Price · USD

2.200

+0.170 (8.37%)

At close: Apr 22, 2024, 4:00 PM

2.190

-0.010 (-0.45%)

After-hours: Apr 22, 2024, 7:18 PM EDT

BriaCell Therapeutics Income Statement

Financials in millions USD. Fiscal year is August - July.

Millions USD. Fiscal year is Aug - Jul.

Year	2023	2022	2021	2020	2019	2018
Selling, General & Admin	7.94	7.27	4.96	1.16	0.78	1.07
Research & Development	15.34	8.02	2.02	1.87	3.08	2.4
Other Operating Expenses	0	0	0	0	0.04	0.37
Operating Expenses	23.27	15.29	6.98	3.03	3.9	3.83
Operating Income	-23.27	-15.29	-6.98	-3.03	-3.9	-3.83
Interest Expense / Income	-2.97	11.55	6.84	0.02	0.02	0.02
Other Expense / Income	-	-	-	0.04	-0.29	0.32
Pretax Income	-20.3	-26.84	-13.82	-3.1	-3.63	-4.17
Net Income	-20.3	-26.84	-13.82	-3.1	-3.63	-4.17
Shares Outstanding (Basic)	16	15	5	1	1	0
Shares Outstanding (Diluted)	16	15	5	1	1	0
Shares Change	0.81%	242.82%	533.09%	23.16%	35.49%	-
EPS (Basic)	-1.30	-1.73	-3.06	-4.34	-6.26	-0.03
EPS (Diluted)	-1.30	-1.73	-3.06	-4.34	-6.26	-0.03
Free Cash Flow	-23.74	-12.48	-7.75	-0.97	-3.19	-3.82
Free Cash Flow Per Share	-1.52	-0.81	-1.72	-1.36	-5.51	-8.93
EBITDA	-23.26	-15.27	-6.96	-3.06	-3.6	-4.14
Depreciation & Amortization	0.02	0.02	0.02	0.01	0.01	0.01
EBIT	-23.27	-15.29	-6.98	-3.08	-3.61	-4.15

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).